The biotech bi-weekly: launching a groundbreaking longevity accelerator, a landmark cell analyzer and prosperous partnerships

Over the last two weeks, several partnerships have formed that have propelled peptide manufacturing, the modernization of a statistical computing environment, the development of novel antibody–drug conjugates and the development of immunotherapies targeting novel, cancer-specific proteins. Plus, funding for longevity research and the announcement of the ELRIG Drug Discovery 2025 keynote speakers. Products Expanding NULISAseq™ CNS Disease Panel 120 with pTau assays Alamar Biosciences (CA, USA), a company powering precision proteomics to enable the earliest detection of disease, recently announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The...